Arvinas, Inc. (ARVN) Doses First Patient in ARV-6723 Phase 1/2 Trial

Arvinas dosed the first patient in a Phase 1/2 trial of ARV-6723, an oral HPK1-targeting PROTAC, as monotherapy and with pembrolizumab in advanced solid tumors.Material DetailsContext by AI AnalystThis is an early-stage clinical milestone expanding Arvinas’ PROTAC platform into immuno-oncology. For…